Valenti, William
Scutaru, Jacob
Mancenido, Michael
Zuppelli, Ashley
Danforth, Alexandra
Corales, Roberto
Hilliard, Shealynn
Funding for this research was provided by:
Gilead Sciences (CO-US-380-4644, CO-US-380-4644, CO-US-380-4644)
Article History
Received: 26 February 2024
Accepted: 5 June 2024
First Online: 10 July 2024
Declarations
:
: This study protocol and informed consent forms were reviewed and approved by WCG IRB (Puyallup, WA). All participants provided written informed consent at their first visit before being enrolled on study.
: Not applicable.
: During the study, author M.M. was on the speaker bureau for ViiV Healthcare and author W.V. was a speaker for Gilead Sciences. Author R.C. was a medical scientist who represented Gilead Sciences in this collaborative study. Authors J.S., A.Z., and M.M. were affiliated with Trillium Health at study initiation and during data collection, but not at time of publication. Author J.S. is currently affiliated with CHEMED, 1771 Madison Ave, Lakewood, NJ 08701. Author A.Z. is currently affiliated with US Medical Affairs, Merck Research Laboratories, Kenilworth, NJ 07033, United States. Author M.M. is currently affiliated with Rochester Regional Health, Rochester, NY, United States.